MedTrace Logo

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

NCT07292012 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-12-18

No results posted yet for this study

Summary

Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease

Conditions

  • Crohn Disease (CD)

Interventions

DRUG

Mirikizumab - SC

SC injections (300 mg) at W12 and every 4 weeks For clinical responders and non-responders

DRUG

Mirikizumab - IV

Mirikizumab induction with IV infusions (900 mg) at week 0, week 4 and week 8.

Sponsors & Collaborators

  • Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

    lead OTHER

Principal Investigators

  • Anthony BUISSON, MD · CHU de Clermont-Ferrand

  • Guillaume LE COSQUER, MD · CHU de Toulouse- Hôpital Rangueil

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2027-07-31
Completion
2029-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07292012 on ClinicalTrials.gov